Literature DB >> 22126283

A role for DOT1L in MLL-rearranged leukemias.

Kathrin M Bernt, Scott A Armstrong.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22126283     DOI： 10.2217/epi.11.98

Source DB:  PubMed          Journal:  Epigenomics        ISSN： 1750-192X            Impact factor:   4.778


× No keyword cloud information.
  25 in total

Review 1.  The upstreams and downstreams of H3K79 methylation by DOT1L.

Authors:  Hanneke Vlaming; Fred van Leeuwen
Journal:  Chromosoma       Date:  2016-01-04       Impact factor: 4.316

2.  Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Authors:  Chenxi Shen; Stephanie Y Jo; Chenzhong Liao; Jay L Hess; Zaneta Nikolovska-Coleska
Journal:  J Biol Chem       Date:  2013-09-01       Impact factor: 5.157

Review 3.  Epigenetic alterations in hematopoietic malignancies.

Authors:  Young Rock Chung; Emma Schatoff; Omar Abdel-Wahab
Journal:  Int J Hematol       Date:  2012-09-27       Impact factor: 2.490

4.  MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.

Authors:  Michael W M Kühn; Michael J Hadler; Scott R Daigle; Richard P Koche; Andrei V Krivtsov; Edward J Olhava; Michael A Caligiuri; Gang Huang; James E Bradner; Roy M Pollock; Scott A Armstrong
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

Review 5.  Emerging concepts of epigenetic dysregulation in hematological malignancies.

Authors:  Panagiotis Ntziachristos; Omar Abdel-Wahab; Iannis Aifantis
Journal:  Nat Immunol       Date:  2016-08-01       Impact factor: 25.606

Review 6.  Disordered epigenetic regulation in MLL-related leukemia.

Authors:  Yue Zhang; Aili Chen; Xiao-Mei Yan; Gang Huang
Journal:  Int J Hematol       Date:  2012-09-29       Impact factor: 2.490

7.  Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts.

Authors:  Florian Perner; Jayant Y Gadrey; Yijun Xiong; Charles Hatton; Benjamin K Eschle; Andreas Weiss; Frédéric Stauffer; Christoph Gaul; Ralph Tiedt; Jennifer A Perry; Scott A Armstrong; Andrei V Krivtsov
Journal:  Blood       Date:  2020-10-22       Impact factor: 22.113

Review 8.  Epigenetic reprogramming in cancer.

Authors:  Mario L Suvà; Nicolo Riggi; Bradley E Bernstein
Journal:  Science       Date:  2013-03-29       Impact factor: 47.728

Review 9.  Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention.

Authors:  Xuejiao Tian; Saiyang Zhang; Hong-Min Liu; Yan-Bing Zhang; Christopher A Blair; Dan Mercola; Paolo Sassone-Corsi; Xiaolin Zi
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

10.  RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation.

Authors:  Jayanth Kumar Palanichamy; Tiffany M Tran; Jonathan M Howard; Jorge R Contreras; Thilini R Fernando; Timothy Sterne-Weiler; Sol Katzman; Masoud Toloue; Weihong Yan; Giuseppe Basso; Martina Pigazzi; Jeremy R Sanford; Dinesh S Rao
Journal:  J Clin Invest       Date:  2016-03-14       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.